King of Prussia, Pennsylvania-based Camber Spine welcomes Max Painter as its new global vice president of sales and marketing.
Max Painter Joins Camber Spine as Global VP
1 min read Premium comments
Secondary#camberspine#maxpainter
Camber Spine is a spine and medical technologies company. Founded in 2010, it focuses on developing “surgeon-designed solutions in MIS [minimally invasive surgery] and minimally disruptive access for the treatment of complex spinal pathology.”
Painter spoke with OTW regarding his decision to join Camber Spine: “One of the main things that drew me to Camber Spine is the company’s acute sensitivity to patient anatomy and outcomes.”
Painter continued, “With that and an emphasis on products that help convert surgeon frustrations to innovative solutions Camber is positioned to make quantum leaps in the spinal fusion market, and I’m excited to have the opportunity to contribute to that success.”
Painter brings more than 20 years of sales and marketing experience to Camber Spine. He has worked in leadership roles at numerous orthopedic and spine companies. His industry experience includes NuVasive, Medtronic, Sofamor Danek, and Johnson & Johnson.
Camber Spine’s leadership is excited to welcome Painter. Company Co-Founder and CEO Daniel Pontecorvo said, “We are excited to have an executive with Max’s [Painter] expertise on our team at Camber Spine.”
Pontecorvo continued, “His track record speaks for itself. As we continue to grow and establish our presence as an emerging global leader in spine technology, Max’s [Painter] leadership and experience will help make that vision a reality.”
Camber Spine has an extensive product portfolio of implants and instruments. It currently has 20 510(k) clearances and over 26 active or issued patents.
The company has global plans for its products. Painter commented, “We’re in the process of assembling a real ‘A Team’ of world-class spinal device sales and marketing professionals to help advance the global adoption of Camber’s innovative surgical solutions. Camber has developed a tremendously unique product portfolio to date.”
Painter continued, “I look forward to the future commercialization of a very full, innovative product pipeline.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.